脂蛋白a抗血管生成机制及其临床应用前景  

Anti-Angiogenesis Mechanism of Lipoprotein a and Its Clinical Application Prospect

作　　者：梁翰阳 袁建松[1] LIANG Hanyang;YUAN Jiansong(Coronary Heart Disease Center Fuwai Hospital,National Centerfor Cardiovascular Disease,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)

机构地区：[1]中国医学科学院北京协和医学院国家心血管病中心阜外医院冠心病中心,北京市100037

出　　处：《中国分子心脏病学杂志》2022年第3期4738-4743,共6页Molecular Cardiology of China

基　　金：中国医学科学院医学与健康科技创新工程(重大协同创新项目,2017-12M-2-005)。

摘　　要：脂蛋白a[Lp(a)]是一种在肝脏合成并含有多种脂质成分的脂蛋白,主要由低密度脂蛋白(LDL)样颗粒和载脂蛋白a[Apo(a)]组成。目前Lp(a)升高已被认为是多种心血管疾病(cardiovascular diseases,CVD)的独立危险因素。除了具备促动脉粥样硬化、促进炎症反应、促进血栓形成等作用外,由于Lp(a)的内含结构与血管抑素具有同源性,Lp(a)潜在的抗血管生成能力也日渐吸引了学界的关注。本文主要从Lp(a)的结构和功能出发,对Lp(a)的抗血管生成机制进行综述,分析Lp(a)内部组分参与抗血管生成的分子机制,并探讨其在临床应用中的前景。Lipoprotein a[Lp(a)]is a kind of lipoprotein synthesized in the liver and mainly composed of low density lipoprotein(LDL)-like particles and apolipoprotein a[Apo(a)].High level of Lp(a)has been considered as an independent risk factor for many cardiovascular diseases(CVD).In addition to promoting atherosclerosis,inflammation and thrombosis,the potential ability of antiangiogenesis has attracted more and more attention because of its homology with angiostatin.Based on the structure and function of Lp(a),we mainly review the anti-angiogenic mechanism of Lp(a),analyzes the molecular mechanism involved in anti-angiogenesis,and discusses the prospect of its clinical application.

关 键 词：脂蛋白A 抗血管生成 心血管疾病 临床应用 

分 类 号：R54[医药卫生—心血管疾病]